Skip to main content
Premium Trial:

Request an Annual Quote

Heiner Dreismann, Thomas Hudson, David Cooper, Didier Hirsch, Hilliard Terry

Premium
Heiner Dreismann has been named to the board of directors at Nanogen, the company said this week.
 
Dreismann is the current CEO of FasTraQ and previously served as president and CEO of Roche Molecular Systems
 
Dreismann became a director of Iconix Biosciences last week and last month became a director of GeneNews, formerly ChondroGene.
 

 
The Ontario Institute for Cancer Research recently named Thomas Hudson as its new president and scientific director.
 
An early member of the Human Genome Project, Hudson was a director at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology, and at the MIT Center for Genome Research. He later became the founder and director of the McGill University and Genome Quebec Innovation Centre, where he will remain until 2007.
 

 
Agilent Technologies this week said that Senior Vice President of Finance and Treasurer David Cooper will leave the company effective Nov. 3 to join Art.com as its CFO.
 
Corporate controller Didier Hirsch will become vice president and controller and Hilliard Terry, director of investor relations, will move into the role of vice president and treasurer at Agilent. Terry will continue to serve in his present position until the company names a successor.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.